[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 541
Citations 0
Capitol Health Call
July 14, 2015

Senator Urges VA to “Break” Patents for High-Cost Hepatitis C Drugs

JAMA. 2015;314(2):115. doi:10.1001/jama.2015.7534

Sen Bernie Sanders (I, Vt) has urged Robert McDonald, secretary of the US Department of Veterans Affairs (VA), to enlist third parties to manufacture the patented hepatitis C drugs in the interest of facilitating cost-effective treatment (http://1.usa.gov/1T1LN0S) for veterans, who are infected at a rate 3 times higher than that of the general US population (http://1.usa.gov/1KK1ZOR). The letter references the drug Solvadi (sofosbuvir), a medication used to treat hepatitis C that is manufactured by Gilead Sciences. The medication is currently priced at $1000 per pill, or $84 000 for a full course of treatment. In his letter, Sanders cited a legal statute that would allow Gilead to seek reimbursement from the VA in federal claims court.

First Page Preview View Large
First page PDF preview
First page PDF preview
×